¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cytotoxic cell protein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • giant cell granuloma
    °Å´ë¼¼Æ÷À°¾ÆÁ¾
  • giant cell myeloma
    °Å´ë¼¼Æ÷°ñ¼öÁ¾
  • giant cell myocarditis
    °Å´ë¼¼Æ÷½É±Ù¿°
  • giant cell pneumonia
    °Å´ë¼¼Æ÷Æó·Å
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾¾ç
  • glandular cell
    »ù¼¼Æ÷, ¼±¼¼Æ÷
  • glial cell
    ½Å°æ¾Æ±³¼¼Æ÷
  • glitter cell
    ¹Ý¦¼¼Æ÷
  • globoid cell
    °ø¸ð¾ç¼¼Æ÷
  • globoid cell leukodystrophy
    °ø¼¼Æ÷¹é»öÁúÀå¾Ö, ±¸Çü¼¼Æ÷¹éÁúµð½ºÆ®·ÎÇÇ
  • glomus cell
    Å丮¼¼Æ÷
  • goblet cell
    ¼úÀܼ¼Æ÷
  • Golgi cell
    °ñÁö¼¼Æ÷
  • gonadotrope cell
    »ý½Ä»ùÀڱؼ¼Æ÷, »ý½Ä¼±Àڱؼ¼Æ÷
  • ganglion cell
    ½Å°æÀý¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • hybrid cell
    ÀâÁ¾¼¼Æ÷
  • hypersensitized cell
    °ú¹Î°¨¼¼Æ÷
  • immunologically competent cell
    (¢¡immunocyte) ¸é¿ª¼¼Æ÷
  • indeterminate cell
    ºÎÁ¤Çü¼¼Æ÷
  • indifferent cell
    ¹«°ü¼¼Æ÷
  • inducer cell
    À¯µµ¼¼Æ÷
  • inflammatory cell
    ¿°Áõ¼¼Æ÷
  • infundibular cell
    ±ò¶§±â¼¼Æ÷
  • intercalated cell
    »çÀ̼¼Æ÷, °³Àç¼¼Æ÷
  • interdental cell
    û°¢Ä¡¾Æ»çÀ̼¼Æ÷, Ä¡°£¼¼Æ÷
  • interstitial cell
    »çÀÌÁú¼¼Æ÷
  • islet cell
    ¼¶¼¼Æ÷
  • islet cell carcinoma
    ¼¶¼¼Æ÷¾ÏÁ¾
  • juvenile cell
    À¯¾à¼¼Æ÷
  • killer cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • ghost cell
    À¯·É¼¼Æ÷(ËôËçËṴ̂).
  • ghost cell glaucoma
    ºó¼¼Æ÷³ì³»Àå, À¯·É¼¼Æ÷³ì³»Àå
  • giant cell aortitis
    °Å´ë¼¼Æ÷¼º ´ëµ¿¸Æ¿°
  • giant cell arteritis
    °Å¼¼Æ÷(¼º) µ¿¸Æ¿°
  • giant cell arteritis=temporal arteritis
    °Å¼¼Æ÷µ¿¸Æ¿°
  • giant cell carcinoma
    °Å¼¼Æ÷¾ÏÁ¾
  • giant cell epulis
    °Å¼¼Æ÷Ä¡ÀºÁ¾.
  • giant cell fibroblastoma
    °Å´ë¼¼Æ÷ ¼¶À¯¸ð¼¼Æ÷Á¾
  • giant cell glioma
    °Å¼¼Æ÷±³Á¾.
  • giant cell granuloma
    °Å´ë¼¼Æ÷ À°¾ÆÁ¾
  • giant cell granuloma,reparative
    ¼öº¹¼º °Å´ë¼¼Æ÷ À°¾ÆÁ¾
  • giant cell histiocytoma
    °Å´ë¼¼Æ÷ Á¶Á÷±¸Á¾
  • giant cell leukemia
    °Å¼¼Æ÷¹éÇ÷º´.
  • giant cell myeloma
    °Å¼¼Æ÷°ñ¼öÁ¾.
  • giant cell myocarditis
    °Å´ë¼¼Æ÷¼º ½É±Ù¿°(¡­ãýÐÉæú)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • activation, polyclonal B cell
    ´Ù¼¼Æ÷±º B¼¼Æ÷Ȱ¼º, ¿©·¯¹«¸® B¼¼Æ÷Ȱ¼º
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç(ÛöÕË ðþåÆ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adcc(antibody dependent cell mediated cytotoxicity)
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øàØÚË¿á¬øàÔ¸àõ)
  • adenoid basal cell carcinoma
    ¼±»ó(àÍßÒ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adenoid squamous cell carcinoma
    ¼±»ó ÆíÆò »óÇǼ¼Æ÷(àÍßÒ ø·øÁ ß¾ù«á¬øà) ¾Ï
  • adult T Cell leukemia virus
    ¼ºÀÎ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • adult T cell leukemia virus (HTLV)
    ¼ºÀÎT¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • adult t-cell leukemia/lymphoma
    ¼º¼÷ T-¼¼Æ÷ ¹éÇ÷º´/¸²ÇÁÁ¾(à÷âÙ¡­á¬øà ÛÜúìÜ»/¡­ðþ)
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • alpha cell
    ¾ËÆÄ¼¼Æ÷
  • alpha cell
    ¾ËÆÄ¼¼Æ÷(¡­á¬øà)
  • alpha cell tumor
    ¾ËÆÄ ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • amacrine cell
    ¾Æ¸¶Å©¸° ¼¼Æ÷
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • nonheme-iron protein
    ºñ(Þª)Èû-ö(ôÑ) ´Ü¹éÁú(Ó±ÛÜòõ)
  • omega protein
    ¿À¸Þ°¡ ´Ü¹éÁú(Ó±ÛÜòõ)
  • peripheral protein
    ÁÖº¯´Ü¹éÁú(ñ²Ü«Ó±ÛÜòõ)
  • polycephalic protein
    º¹ÇÕ±â´É ´Ü¹éÁú(ÜÜùêѦÒöÓ±ÛÜòõ)
  • polyfunctional protein
    ´Ù±â´É ´Ü¹éÁú(ÒýѦÒöÓ±ÛÜòõ)
  • P protein
    P ´Ü¹éÁú(Ó±ÛÜòõ)
  • prepriming protein
    ÇÁ·¹ÇÁ¶óÀÌ¹Ö ´Ü¹éÁú(Ó±ÛÜòõ)
  • primary derived protein
    ÀÏÂ÷ À¯µµ ´Ü¹éÁú(ìéó­ë¯ÓôÓ±ÛÜòõ)
  • primary protein derivative
    ÀÏÂ÷ ´Ü¹éÁúÀ¯µµÃ¼
  • protein
    ´Ü¹éÁú(Ó±ÛÜòõ)
  • protein A
    ´Ü¹éÁú(Ó±ÛÜòõ) A
  • protein biosynthesis
    ´Ü¹éÁú »ýÇÕ¼º(Ó±ÛÜòõßæùêà÷)
  • protein blotting
    ´Ü¹éÁú(Ó±ÛÜòõ) ºí·ÔÆÃ
  • protein-bound iodine
    ´Ü¹éÁú°áÇÕ(Ó±ÛÜòõÌ¿ùê) ¿äµå
  • protein C
    ´Ü¹éÁú(Ó±ÛÜòõ) C
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
PP diphosphate group; emphysema [pink puffers]; near point of accommodation [Lat. punctum proximum]; pa...
PPD packs per day; paraphenylenediamine; percussion and postural drainage; permanent partial disability;...
PPP pain perception profile; palatopharyngoplasty; palmoplantar pustulosis; pentose phosphate pathway; p...
PS pacemaker syndrome; paired stimulation; paradoxical sleep; paraspinal; parasympathetic; Parkinson sy...
PSP pancreatic spasmolytic peptide; paralytic shellfish poisoning; parathyroid secretory protein; period...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
ADCC Antibody Dependent Cell Cytotoxicity
ADCC Antibody Dependent Cell-Mediated Cytotoxicity
ADCC Antibody-dependent cell-mediated cytolysis
AFC Antibody-forming cell
PCNA Antiproliferating cell nuclear antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • laminar II cell
    Á¦ 2Ãþ ¼¼Æ÷
  • laminar ¥± cell
    Á¦ 2Ãþ ¼¼Æ÷
    Á¦ 2ÃþÀÇ ¼¼Æ÷´Â 2Á¾·ù°¡ Àִµ¥ ÃþÀÇ ¹Ù±ù ÂÊ 1/4´Â ´õ¿í ÀÛÀº ¼¼Æ÷·Î ÅëÁõ°ú ¿­¿¡ ´ëÇÑ ¼ö¿ëü¸¦ °¡Áö°í ÀÖ°í, ¾È ÂÊ 3/4´Â Á» ´õ Å« ¼¼Æ÷·Î ¹«µ¶¼ºÀÇ ±â°è¼ö¿ëü¸¦ °¡Áö°í ÀÖ´Ù.
  • Langerhans cell
    ¶û°Ô¸£Çѽº ¼¼Æ÷, Ç¥ÇÇ¼Ó Å« Æ÷½Ä¼¼Æ÷
    µ¿ÀǾî=intrae
  • large cell
    ´ë¼¼Æ÷
    ƯÁ¤ ÀÌÀ¯°¡ ÀÖ¾î
  • LE cell
    LE ¼¼Æ÷, È«¹Ý¼º ³¶Ã¢ ¼¼Æ÷
    µÕ±Û°í, ±ÕÁú·Î º¸ÀÌ´Â ºÀÀÔü¸¦ ޽ÄÇÑ ¼º¼÷ È£Áß±¸¼º ´ÙÇÙ ¹éÇ÷±¸. ±× ºÀÀÔü ÀÚü´Â ´Ù¸¥ È£Áß±¸¿¡¼­ À¯·¡µÈ °ÍÀÌ´Ù. È«¹Ý¼º ·çǪ½º¿¡ ƯÀ¯ÇÑ °ÍÀÌÁö¸¸ °áÇÕ Á¶Á÷ÀÇ À¯»çÇÑ Áúȯ¿¡¼­µµ °üÂûµÈ´Ù.
  • lingual benign giant cell tumor
    ¾ç¼º °Å´ë ¼¼Æ÷ ¼³ Á¾¾ç
  • lupus erythematosus cell
    È«¹Ý¼º ·çǪ½º ¼¼Æ÷, È«¹Ý¼º ³¶Ã¢ ¼¼Æ÷
  • M-cell
    M ¼¼Æ÷
  • malignant plasma cell
    ¾Ç¼º ÇüÁú ¼¼Æ÷
  • mast cell
    ºñ¸¸ ¼¼Æ÷
    µ¿¹°ÀÇ °áÇÕ Á¶Á÷ ¼Ó¿¡ ÀÖ´Â ¼¼Æ÷·Î ¸¸¼º ¿°Áõ¿¡ À־ÀÇ Áõ½Ä Á¶Á÷ ¼Ó¿¡ ¸¹¾Æ¼­ ÀÌ·± À̸§ÀÌ ºÙ¾ú´Ù. ÀÌ ¼¼Æ÷ ¼Ó¿¡´Â ¸¹Àº °ú¸³ÀÌ µé¾îÀÖ¾î ¿°Áõ ¹ÝÀÀ¿¡ °ü¿©Çϰí ÀÖ´Ù.
  • mature daughter cell
    ¼º¼÷ÇÑ µþ ¼¼Æ÷
  • mean cell

    mean cell hemoglobin (Æò±Õ ÀûÇ÷±¸ Ç÷»ö¼Ò

  • mean cell volume
    Æò±Õ ÀûÇ÷±¸ ¿ëÀû
  • megakaryocytic blast cell
    °ÅÇÙ¸ð±¸
  • memory T cell
    ±â¾ï T ¼¼Æ÷
    Ç׿øÀÌ µé¾î¿ÔÀ» ¶§ B ¼¼Æ÷°¡ Èä¼±À» ÀÚ±ØÇÏ¿© T ¸²ÇÁ±¸¸¦ »ý»ê, ºÐÈ­ÇÒ ¶§ Ç׿ø-Ç×ü ¹ÝÀÀÀ» ÇÏÁö ¾Ê°í ³²¾Æ ±× Ç׿øÀ» ±â¾ïÇÏ¿© 2Â÷ Ç׿ø-Ç×ü ¹ÝÀÀ¿¡ ½Å¼ÓÈ÷ ¹ÝÀÀÀ» º¸À̵µ·Ï ÇÏ´Â T ¼¼Æ÷.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
protein conformation The characteristic 3-dimensional shape of a protein, imposed upon it by the secondary and tertiary structure of the peptide chain. This stage in the structure of a protein describes the highest level of organization in overall structure assumed by multimeric proteins (aggregates of more than one polypeptide chain). This is the fourth folding level of protein building.
(12 Dec 1998)
protein crystallization This is an essential process in determining a protein's three-dimensional structure, and hence in using that information to design drugs.
(14 Nov 1997)
protein-D-aspartate methyltransferase <enzyme> For protein carboxymethylases consider also protein o-methyltransferase
Registry number: EC 2.1.1.77
Synonym: d-aspartyl-l-isoaspartyl methyltransferase, protein d-aspartate-l-isoaspartate methyltransferase, protein l-isoaspartate o-methyltransferase, protein-beta-aspartate methyltransferase, protein-l-isoaspartate methyltransferase, protein l-isoaspartyl methyltransferase, isoaspartyl-aspartyl protein methyltransferase, protein-d-asp methyltransferase, l-isoaspartyl protein carboxymethyltransferase, pcm gene product, pcmt1 gene product
(26 Jun 1999)
protein deficiency A nutritional condition produced by a deficiency of proteins in the diet, characterised by adaptive enzyme changes in the liver, increase in amino acid synthetases, and diminution of urea formation, thus conserving nitrogen and reducing its loss in the urine. Growth, immune response, repair, and production of enzymes and hormones are all impaired in severe protein deficiency. Protein deficiency may also arise in the face of adequate protein intake if the protein is of poor quality (i.e., the content of one or more amino acids is inadequate and thus becomes the limiting factor in protein utilization).
(12 Dec 1998)
protein disulfide-isomerase <enzyme> An enzyme that catalyses the rearrangement of disulfide bonds within proteins during folding. It is a monomer identical to one of the subunits of procollagen-proline dioxygenase.
Chemical name: Protein disulfide-isomerase
Registry number: EC 5.3.4.1
(12 Dec 1998)
protein disulfide reductase (glutathione) <enzyme> An enzyme that catalyses the reduction of a protein-disulfide in the presence of glutathione, forming a protein-dithiol. Insulin is one of its substrates.
Chemical name: Glutathione:protein-disulfide oxidoreductase
Registry number: EC 1.8.4.2
(12 Dec 1998)
protein-energy malnutrition The lack of sufficient energy or protein to meet the body's metabolic demands, as a result of either an inadequate dietary intake of protein, intake of poor quality dietary protein, increased demands due to disease, or increased nutrient losses.
(12 Dec 1998)
protein engineering Normally means the use of recombinant DNA technology to produce proteins with desired modifications in the primary sequence.
See: site specific mutagenesis.
(18 Nov 1997)
protein factor The factor (6.25) by which the nitrogen content of a protein is multiplied to give the amount of protein.
(05 Mar 2000)
protein fever Fever produced by the injection of foreign protein, such as milk.
(05 Mar 2000)
protein folding A rapid biochemical reaction involved in the formation of proteins. It begins even before a protein has been completely synthesised and proceeds through discrete intermediates (primary, secondary, and tertiary structures) before the final structure (quaternary structure) is developed.
(12 Dec 1998)
protein G Protein from Group C Streptococci that binds the Fc portion of IgG. Is less species specific than Protein A.
(18 Nov 1997)
protein geranylgeranyltransferase <enzyme> Involved in protein isoprenylation; transfers geranylgeranyl group to cys fourth from the c-terminal of GTP-binding proteins; amino acid sequence of beta subunit of ggtase-i known; genbank l24116; see also rab, ras, and rhoa p21 geranylgeranyl- transferases and component a, rab geranylgeranyltransferase
Registry number: EC 2.5.1.-
Synonym: protein ggtase, geranylgeranyltransferase type-i, ggtase-i, geranylgeranyl-protein transferase type 1
(26 Jun 1999)
protein-glutamine gamma-glutamyltransferase <enzyme> An enzyme that catalyses the reaction of protein glutamine and an alkylamine to yield protein n(5)-alkylglutamine and ammonia. The gamma-carboxamide groups of peptide-bound glutamine residues act as acyl donors, and the 6-amino groups of protein- and peptide-bound lysine residues act as acceptors, to give intra- and inter-molecular n(6)-(5-glutamyl)lysine crosslinks. In the epidermis these cross-linked proteins are involved in the formation of the cornified envelope of the stratum corneum cells. In the plasma, the transglutaminase is called factor xiiia, the activated form of factor xiii. The crosslinking results in the stabilization of the fibrin clot.
Pharmacological action: coagulants.
Chemical name: Protein-glutamine:amine gamma-glutamyltransferase
Registry number: EC 2.3.2.13
(12 Dec 1998)
protein-histidine kinase <enzyme> Sass involved in transduction of starvation and cell density inputs; hkna isolated from bacillus thuringiensis; ciah isolated from streptococcus pneumoniae; do not confuse with plp1 protein
Registry number: EC 2.7.3.-
Synonym: histidine protein kinase, histidine kinase, hkna gene product, ciah gene product, kinc gene product, prrb gene product, plec gene product, mxcq gene product, rese gene product, hpka gene product, comd gene product, plpa gene product (phytochrome-like), divj gene product, sensor histidine kinase, sass gene product
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
ÅëÇÕ°Ë»ö ¿Ï·á